



Published in final edited form as:

Drug Alcohol Rev. 2010 November ; 29(6): 623–630. doi:10.1111/j.1465-3362.2010.00238.x.

Conducting economic evaluations of screening and brief intervention for hazardous drinking: Methods and evidence to date for informing policy

Alexander J. Cowell, PhD, Jeremy W. Bray, PhD, Michael J. Mills, MA, and Jesse M. Hinde, BA

RTI International, Research Triangle Park, NC

Abstract

Issues—Many policy review articles have concluded that alcohol screening and brief intervention (SBI) is both cost-effective and cost-beneficial. Yet a recent cost-effectiveness review for the United Kingdom’s National Institute for Health and Clinical Excellence suggests that these conclusions may be premature.

Approach—This article offers a brief synopsis of the various types of economic analyses that may be applied to SBI, including cost analysis, cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis, and other types of economic evaluation. A brief overview of methodological issues is provided, and examples from the SBI evaluation literature are provided.

Key Findings, Implications, and Conclusions—The current evidence base is insufficient to draw firm conclusions about the cost, cost-effectiveness, or cost-benefit of SBI and about the impact of SBI on health care utilisation.

Keywords

screening and brief intervention; hazardous drinking; economic evaluation; cost analysis; cost-effectiveness analysis; cost-utility analysis; cost-benefit analysis

Introduction

Numerous studies have shown that screening and brief intervention (SBI) is effective in reducing alcohol use and associated problems for most populations at risk [1–9]. Furthermore, several review articles have concluded that alcohol SBI is a cost-effective preventive service [8,10–11], and many policy makers are advocating that SBI be used as part of standard clinical practice (e.g., [12–14]). Despite the widespread perception that SBI is cost-effective, the scientific evidence base supporting this conclusion is relatively weak, and more research is needed before definitive policy recommendations can be made [15]. This article presents an overview of the types of economic analysis methods that are germane to SBI research.

Alcohol screening is typically based on a structured instrument (e.g., the Alcohol Use Disorders Identification Test [16]). The brief intervention (BI) is any therapeutic or preventive consultation of short duration (one to five sessions) undertaken by a health care professional [17–18]. It typically comprises assessment, feedback, information, advice, and

the provision of self-help materials [19]. The majority of the SBI literature focuses on one key target population, hazardous drinkers [20], typically defined as people who drink above guidelines for safe drinking but who would not be considered dependent. The dimensions by which SBI may vary include the screening tools used, the delivery approach, the setting, the country or region, and the staff delivering the intervention. These dimensions will determine both the cost of the intervention and its impact on outcomes.

In an era of limited resources in most health care systems, decision makers frequently demand that interventions and treatments be justified fiscally as well as clinically. Although a single session of SBI for hazardous alcohol use may be expected to be relatively cheap, SBI as a public health program may have a significant fiscal impact when applied to a large population. Furthermore, models of SBI implementation will vary considerably in their implications for resource use, based on the duration and number of BI sessions and on the qualifications of the interventionist. Economic evaluation of SBI is therefore needed because it involves assessing resource allocation implications of competing health care programs. The analytic approaches in economic evaluation determine the cost of SBI and/or the value of outcomes in money terms or some other standard unit. Economic evaluation helps decision makers set budgets and choose among the myriad alternative uses for scarce health care resources. Key studies and texts for conducting economic evaluation on SBI are noted throughout this review. Reference texts for conducting economic evaluation in health care more generally are Gold et al. [21] and Drummond et al. [22]. Thorough reviews of specific types of economic evaluation when applied to SBI can be found in Babor et al. [23] and Latimer et al. [15].

Economic Evaluation: Methods and Summary of Evidence

There are five broad approaches to economic evaluation (Table 1). The first four approaches require estimating the value of SBI and are inter-related (Figure 1): cost analysis, cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis (CBA). Cost analysis estimates the value of resources used to deliver SBI. CEA compares the relative costs and effectiveness of two or more alternative programmes using the incremental cost-effectiveness ratio (ICER), which expresses the additional cost required to improve effectiveness by one unit. CUA is a form of CEA that has a standardised metric of effectiveness that indirectly reflects utility (or satisfaction). CBA estimates the value of all relevant outcomes of SBI and weighs that value against its costs. The fifth approach to economic evaluation examines the impact of SBI on one or more economic outcomes (e.g., number of outpatient visits).

Within each approach, the perspective determines which stakeholders' costs, outcomes, and benefits are included. A societal perspective—which includes all stakeholders' costs and outcomes—is often recommended and used (e.g., [21]). However, narrower perspectives, such as the health care system, are often useful for forming policy and determining whether to adopt services [22].

Cost analysis

A cost analysis is the first step in a full economic evaluation of SBI and provides critical information beyond its contribution to CEA, CUA, or CBA [22]. A detailed cost analysis of SBI can be used to accurately project budgets under different configurations of resources. Cost analysis by itself may not incorporate information on the impact on outcomes of SBI. Thus, cost minimisation analysis—choosing an intervention based on lowest costs alone—is not recommended as a valid method for making policy recommendations [22].

Evaluators may choose to add future health care costs to the costs of the intervention. This approach is often taken in the broader health economics literature [24] and sometimes taken in the literature on substance use interventions [25]. Alternatively, future health care costs may be omitted from the cost of the intervention and instead counted as a benefit in a CBA as an averted health care cost. This approach is taken by many studies on substance use and several studies on SBI (e.g., [16,26–31]). A recent study uses both alternatives, by excluding future health care costs from the intervention cost in the CEA, but including them in the intervention cost of a CUA [32]. Because future health care costs may be legitimately used differently in economic evaluations, it is important that researchers report how future health care costs are included (see Drummond et al. [22], pages 17–22).

Two features of SBI are particularly important for conducting cost analysis. First, data on the cost of SBI may require primary data collection methods. In some countries, such as the United States, reliable data on the provision of SBI may not be available in administrative records because it is not a reimbursable service in every state or health plan. Second, regardless of how cost data on SBI are collected, it is important that they be as accurate as possible. SBI is brief by design. Thus, estimating the duration of screening to be 2 minutes rather than 1 minute, for example, doubles the cost estimate of screening. This will clearly affect the budget for policy makers trying to fund a universal screening programme. Systematic methods to estimate all resources used in SBI help ensure the accuracy and comparability of cost estimates. An example among several available protocols and versions [33–37] is the Substance Abuse Services Cost Analysis Program (SASCAP) [38].

Estimates of the cost of the intervention component alone of SBI (i.e. excluding future health care costs) [25–26,29,39–45] vary so widely as to prohibit drawing conclusions about the typical cost of providing SBI. The variation in cost is illustrated by two studies [29,41] in the setting with the most studies, the primary care/general practitioner setting. The cost of screening varies from \$0.52 [41] to \$181.41 [29], and the cost of BI varies from between \$3.24 and \$4.29 (depending on the specific intervention) [41] to \$89.66 [29].

The literature provides limited guidance on the source of variability in cost estimates, in large part because there are so few stand-alone cost studies in the peer-review literature. Most published cost estimates are presented as part of a CEA, CUA, or CBA and thus provide insufficient detail on the cost analysis methods. Thus, it is currently not possible to determine whether differences in costs are driven by differences in study methods, settings, staffing, screening tool, delivery, or target population.

Cost-effectiveness analysis

CEA compares two or more treatments using the ICER—the difference in costs between two interventions divided by the difference in outcomes [21]. The ICER reveals how much more it costs to achieve one additional unit of outcome with one alternative compared to another. For example, an ICER could show that SBI Programme A costs \$1,000 per person more than Programme B to reduce average drinks per week by one. The ICER is often compared to willingness to pay, which is the stakeholder's implicit value of the outcome. The most desirable intervention among a set of mutually exclusive choices is the most effective intervention with an ICER that is less than the willingness to pay for the intervention. For a clear and concise summary of the decision rules to use when interpreting CEAs, see Bala and Zarkin [46].

Two key issues when conducting CEA are estimating sampling variation in the estimates and choosing the outcome to be analysed. Because the ICER is the ratio of two random variables, incorporating statistical variation in costs and effectiveness into CEA to obtain a confidence interval or standard error is not straightforward. Approaches include using

bootstrap techniques to calculate a confidence interval or standard error [47] or using cost-effectiveness acceptability curves (CEACs) (e.g., [48–50]) when comparing two interventions and cost-effectiveness acceptability frontiers (CEAFs) when comparing three interventions or more (e.g., [51]). CEACs and CEAFs graphically represent the probability that a particular intervention is optimal over a range of willingness-to-pay values.

With regard to choosing the outcome to be analysed, any relevant outcome, such as drinks per week, can be used if it is relevant for all interventions under consideration [22]. However, because SBI may yield several worthwhile outcomes, the ICER for one outcome measure may yield a different policy implication than the ICER for another outcome measure [52]. The literature on substance use has yet to agree on a standard, aggregate outcome and has yet to adopt utility measures in CUA (discussed below) [53].

Although several review articles conclude that SBI is cost-effective [8,10–11], CEA results vary considerably. This variation reflects the issues underlying the supporting cost analyses, previously discussed, and the fact that many studies use different metrics for outcomes. The most commonly used outcome in CEA studies of SBI is the average number of drinks per week [16]. Kunz et al. [43] and Barrett et al. [25] both use average drinks per week as a metric and are set in an emergency department; however, the two are set in different countries. Kunz et al. is set in the United States and finds an ICER of \$273 per 1-drink reduction, whereas Barrett et al. is set in the United Kingdom and finds an ICER of \$39.

Cost-utility analysis

CUA is a form of CEA that expresses outcomes in a common metric, typically the Quality Adjusted Life Year (QALY) [21]. QALYs assign a quality weight to each additional year of life generated by a treatment, where 1.0 indicates perfect health and 0 indicates death. Although QALYs can be used to compare a wide range of programmes with each other, they can be difficult to estimate for services that are expected to have only small effects on the patient's quality of life in the near term or length of life over the long term. QALY weights have yet to be constructed for every substance use measure, including hazardous drinking. Moreover, it is unlikely that any utility measure would be able to capture the impact of alcohol use on important societal outcomes, such as crime [52].

CUA often relies on modeling to obtain QALY impacts. The outcome available in studies is typically alcohol consumption 1 year after the intervention, and this must then be converted into a long-term impact [54]. A commonly used method is Markov modeling, which models transitions between a limited number of states (e.g., [9]). More sophisticated modeling allows for individual-level heterogeneity [55]; such modeling has recently been used in the economics of substance use [56], but not specifically for SBI. It should be noted that the conclusions drawn from modeling will depend on the validity of the model.

A recent review of CUA of SBI for the United Kingdom's National Institute for Health and Clinical Excellence (NICE) [15] bases recommendations on four studies that met the review criteria [9,11,57–58]. The report concludes that, based on standard willingness-to-pay values, SBI in the United Kingdom likely would be cost-effective in primary care settings but that sufficient evidence does not exist to make a similar conclusion with regard to emergency department and hospital settings.

Cost-benefit analysis

CBA directly compares the costs of SBI to the value of all relevant outcomes (e.g., the value of avoided health care services or car crashes) and thus can answer the question of whether an intervention is worth the cost [22]. CBA may also be conducted by multiplying the

estimated QALYs gained from an intervention by willingness-to-pay estimates (discussed in the CEA section above) and comparing the result to the intervention's costs.

Conceptually, because CBA allows direct comparison of costs to benefits, it may provide clear guidance on which interventions should be adopted independent of the alternatives. Practically, however, CBAs are often difficult to implement. It is challenging to estimate values for all relevant outcomes of the interventions because many clinically relevant outcomes, such as reduced alcohol use, may not be easily expressed in monetary terms. Furthermore, it may not be possible to consistently measure all relevant outcomes of an intervention.

CBA results are typically computed as either net benefit estimates or benefit-cost ratios. To calculate the net benefit, the sum of costs is subtracted from the sum of benefits; to calculate benefit-cost ratios, benefits are expressed as a percentage of costs [22]. Perhaps because of the practical challenges of CBA, only four publications from two separate projects conduct a formal CBA. Although all four suggest that SBI is cost-beneficial [26,28–29,59], the limited number of studies suggests caution should be used in drawing policy conclusions.

Analysis of the impact of SBI on economic outcomes

Much of the current literature on the economic evaluation of SBI examines the impact of SBI on economic outcomes, primarily health care utilisation [42,60–72]. All but one of these studies keep utilisation in its natural units, such as outpatient visits, rather than convert utilisation into costs. There is no comprehensive review of the impact of SBI on health care utilisation. Two reviews focusing on the impact of SBI on alcohol use secondarily address health care utilisation. The first examines four studies in emergency department settings and suggests that SBI reduces health care utilisation [64]. The second examines 30 studies in primary care settings and found only 1 study where SBI was associated with reductions in health care utilisation [73].

A related approach to economic evaluation, cost-offset analysis, limits the perspective of analysis to the health care system. The analysis assesses the cost of the intervention against the value of any reductions in health care utilisation. Although cost-offset analysis is well established in the behavioral health arena broadly (e.g., [74–77]), few studies assess the cost-offset of SBI specifically. The cost-offset findings for SBI are mixed. For example, one study set in the emergency room finds health care cost savings [42], whereas another that focuses on older adults in primary care settings finds little effect [29]. Other studies wrap possible medical provider health care cost savings into a broader perspective CEA, CUA, or CBA (e.g., [11,25,29]), discussed previously. It is currently unclear the degree to which health care cost savings drive the results of these broader analyses.

Discussion

Economic evaluation methods are increasingly being used to support policy efforts to disseminate alcohol SBI. This paper has presented a brief overview of the five types of economic evaluations and the SBI literature for each. Despite a widespread perception among policy makers that SBI is cost-effective and cost-beneficial, the peer-reviewed literature supporting this conclusion is largely insufficient [15]. Three limitations of the evidence base for making policy decisions are most notable. First, the cost analyses that underpin the CEA and CBA analyses provide a very large range of cost estimates that makes it difficult for decision makers to appropriately budget services. These studies typically do not provide sufficient details about their cost analysis methodology to allow an informed understanding of why SBI cost estimates vary so widely. The increasing availability of

online appendices that are subject to peer-review scrutiny is perhaps one solution to providing the necessary detail on intervention costs.

A second limitation of the current literature is that CEA studies of SBI do not use consistent and uniform outcomes, such as QALYs. Caution should always be applied in basing policy solely on potential cost savings to the health care system. Balancing cost implications against a consistent health outcome measure using CEA or CUA is thus needed. The variation in outcomes coupled with the variation in the underlying cost estimates, however, prohibits drawing firm conclusions about the cost-effectiveness of SBI in all health care settings or making comparative assessments of one SBI model to another. To help guide policy, it is recommended that a core set of outcomes be determined and used.

A third limitation is that conclusions of policy review articles are typically based on a handful of studies that show SBI to be cost-beneficial while ignoring other studies, many of which fail to find statistically significant cost savings associated with SBI. Although many economic evaluations focus on the impact of SBI on health care utilisation, there has been no comprehensive, systematic review or meta-analysis of these studies. Health policy requires such a study so that resources can be allocated appropriately.

Acknowledgments

This study was funded by grant R01 AA013925 from the National Institute on Alcohol Abuse and Alcoholism (United States). The authors would like to thank session participants at the 2009 International Conference on Brief Interventions for Alcohol Problems for their comments.

References

1. Wallace P, Cutler S, Haines A. Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. *BMJ*. 1988; 297:663–668. [PubMed: 3052668]
2. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. *Addiction*. 1993; 88:315–336. [PubMed: 8461850]
3. Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. *Addiction*. 2002; 97:279–292. [PubMed: 11964101]
4. Wilk AI, Jensen NM, Havinghurst TC. Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. *J Gen Intern Med*. 1997; 12:274–283. [PubMed: 9159696]
5. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers. *JAMA*. 1997; 277:1039–1045. [PubMed: 9091691]
6. Ockene JK, Adams A, Hurley TG, Wheeler EV, Hebert JR. Brief physician- and nurse practitioner-delivered counseling for high-risk drinkers. *Arch Intern Med*. 1999; 159(18):2198–2205. [PubMed: 10527297]
7. Bernstein J, Bernstein E, Tassiopoulos K, Huren T, Levenson S, Hingson R. Brief intervention at a clinic visit reduced cocaine and heroin use. *Drug Alcohol Depend*. 2005; 77(1):49–59. [PubMed: 15607841]
8. Coffield AB, Harris JR, Richland JH. Priorities among recommended clinical preventive services. *Am J Prev Med*. 2001; 21(1):1–9. [PubMed: 11418251]
9. Chisholm D, Rehm J, van Ommeren M, Monteiro M, Frick U. The comparative cost-effectiveness of interventions for reducing the burden of heavy alcohol use. *J Stud Alcohol*. 2004; 65:782–793. [PubMed: 15700517]
10. Broskowski, A.; Smith, S. Estimating the cost of preventive services in mental health and substance abuse under managed care. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2001.

11. Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse: ranking its health impact and cost effectiveness. *Am J Prev Med.* 2008; 34(2):143–152. [PubMed: 18201645]
12. Office of National Drug Control Policy (ONDCP). The national drug control strategy: update. Washington, DC: Office of National Drug Control Policy; 2003.
13. Substance Abuse and Mental Health Services Administration (SAMHSA). Screening, brief intervention, and referral to treatment: new populations, new effectiveness data. 2009 [cited 2010 July 12]. Available at: http://www.samhsa.gov/samhsaNewsletter/Volume_17_Number_6/SBIRT.aspx.
14. George Washington University Medical Center. Ensuring solutions to alcohol problems: costs and benefits. 2009 [cited 2009 December 29]. Available at: http://www.ensuringsolutions.org/resources/resources_list.htm?cat_id=987.
15. Latimer, N.; Guillaume, L.; Goyder, E.; Chilcott, J.; Payne, N. Prevention and early identification of alcohol use disorders in adults and young people: screening and brief interventions: cost effectiveness review. Sheffield: ScHARR Public Health Collaborating Centre; 2009.
16. Babor TF, Higgins-Biddle JC, Dausser D, Burlinson JA, Zarkin GA, Bray J. Brief interventions for at-risk drinking: patient outcomes and cost-effectiveness in managed care organizations. *Alcohol Alcohol.* 2006; 41(6):624–631. [PubMed: 17035245]
17. Vasilaki EI, Hosier SG, Cox WM. The efficacy of motivational interviewing as a brief intervention for excessive drinking: a meta-analytic review. *Alcohol Alcohol.* 2006; 41(3):328–335. [PubMed: 16547122]
18. Aalto M, Seppa K, Mattila P, et al. Brief intervention for male heavy drinkers in routine general practice: a three-year randomized controlled study. *Alcohol Alcohol.* 2001; 36(3):224–230. [PubMed: 11373259]
19. Beich A, Gannik D, Malterud K. Screening and brief intervention for excessive alcohol use: qualitative interview study of the experiences of general practitioners. *BMJ.* 2002; 325:870–875. [PubMed: 12386040]
20. Heather N. Interpreting the evidence on brief interventions for excessive drinkers: the need for caution. *Alcohol Alcohol.* 1995; 30:287–296. [PubMed: 7545982]
21. Gold, MR.; Siegel, JE.; Russell, LB.; Weinstein, MC., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
22. Drummond, MF.; Sculpher, MJ.; Torrance, GW.; O'Brien, BJ.; Stoddart, GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2006.
23. Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. *Subst Abus.* 2007; 28(3):7–30. [PubMed: 18077300]
24. Birch S, Donaldson C. Applications of cost-benefit analysis to health care. Departures from welfare economic theory. *J Health Econ.* 1987; 6:211–225. [PubMed: 10312255]
25. Barrett B, Byford S, Crawford MJ, et al. Cost-effectiveness of screening and referral to an alcohol health worker in alcohol misusing patients attending an accident and emergency department: a decision-making approach. *Drug Alcohol Depend.* 2006; 81:47–54. [PubMed: 16006055]
26. Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. *Med Care.* 2000; 38(1):7–18. [PubMed: 10630716]
27. Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. *Alcohol Clin Exp Res.* 2002; 26(1):36–43. [PubMed: 11821652]
28. Mundt MP, French MT, Roebuck MC, Manwell LB, Barry KL. Brief physician advice for problem drinking among older adults: an economic analysis of costs and benefits. *J Stud Alcohol.* 2005; 66(3):389–394. [PubMed: 16047528]
29. Mundt MP. Analyzing the cost and benefits of brief intervention. *Alcohol Research & Health.* 2006; 29(1):34–36. [PubMed: 16767851]
30. Zarkin GA, Bray JW, Aldridge A, et al. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. *Arch Gen Psychiatry.* 2008; 65(10):1214–1221. [PubMed: 18838638]

31. Zarkin GA, Bray JW, Aldridge A, et al. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study. *Med Care*. 2010; 48(5):396–401. [PubMed: 20393362]
32. Neighbors CJ, Barnett NP, Rohsenow DJ, Colby SM, Monti PM. Cost-effectiveness of a motivational intervention for alcohol-involved youth in a hospital emergency department. *J Stud Alcohol Drugs*. 2010; 71(3):384–394. [PubMed: 20409432]
33. French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP). *J Subst Abuse Treat*. 1997; 14(5):445–455. [PubMed: 9437614]
34. Yates, BT. Applied social research methods series. Thousand Oaks, CA: Sage Publications; 2006. Analyzing costs, procedures, processes, and outcomes in human services: an introduction.
35. Cowell AJ, Pollio DE, North CS, Stewart AM, McCabe MM, Anderson DW. Deriving service costs for a clubhouse psychosocial rehabilitation program. *Adm Policy Ment Health*. 2003; 30(4): 323–340. [PubMed: 12870558]
36. Zarkin GA, Bray JW, Mitra D, Cisler RA, Kivlahan DR. Cost methodology of COMBINE. *J Stud Alcohol Suppl*. 2005; (15):50–55. discussion 33. [PubMed: 16223056]
37. Beaston-Blaakman A, Shepard D, Horgan C, Ritter G. Organizational and client determinants of cost in outpatient substance abuse treatment. *J Ment Health Policy Econ*. 2007; 10(1):3–13. [PubMed: 17417043]
38. Zarkin GA, Dunlap LJ, Homs G. The Substance Abuse Services Cost Analysis Program (SASCAP): a new method for estimating drug treatment services costs. *Eval Program Plann*. 2004; 27(1):35–43.
39. Wutzke SE, Shiell A, Gomel MK, Conigrave KM. Cost effectiveness of brief interventions for reducing alcohol consumption. *Soc Sci Med*. 2001; 52:863–870. [PubMed: 11234861]
40. Kaner E, Lock C, Heather N, McNamee P, Bond S. Promoting brief alcohol intervention by nurses in primary care: a cluster randomised controlled trial. *Patient Educ Couns*. 2003; 51:277–284. [PubMed: 14630384]
41. Zarkin GA, Bray JW, Davis KL, Babor TF, Higgins-Biddle JC. The costs of screening and brief intervention for risky alcohol use. *J Stud Alcohol*. 2003; 64(6):849–857. [PubMed: 14743949]
42. Gentilello LM, Ebel BE, Wickizer TM, Salkever DS, Rivara FP. Alcohol interventions for trauma patients treated in emergency departments and hospitals: a cost benefit analysis. *Ann Surg*. 2005; 241(4):541–550. [PubMed: 15798453]
43. Kunz FM, French MT, Bazargan-Hejazi S. Cost-effectiveness analysis of a brief intervention delivered to problem drinkers presenting at an inner-city hospital emergency department. *J Stud Alcohol*. 2004; 65:363–370. [PubMed: 15222593]
44. Tolley K, Rowland N. Identification of alcohol-related problems in a general hospital setting: a cost effectiveness evaluation. *Br J Addict*. 1991; 86:429–438. [PubMed: 1905168]
45. Ryder DE, Edwards T. Screening for alcohol related problems in general hospitals: the cost and savings of brief intervention. *J Subst Use*. 2000; 4:211–215.
46. Bala M, Zarkin GA. Application of cost-effectiveness analysis to multiple products: a practical guide. *Am J Manag Care*. 2002; 8:211–218. [PubMed: 11915971]
47. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost effectiveness ratios: a comparison of four methods. *Health Econ*. 1997; 6:243–352. [PubMed: 9226142]
48. The UKATT Research Team. Cost-effectiveness of treatment for alcohol problems: findings of the randomised United Kingdom Alcohol Treatment Trial. *BMJ*. 2005; 331:544–548. [PubMed: 16150765]
49. Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Econ*. 2001; 10:779–787. [PubMed: 11747057]
50. Conigliani C, Tancredi A. Bayesian model averaging approach for cost-effectiveness analyses. *Health Econ*. 2009; 18(7):807–821. [PubMed: 18792078]
51. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). *Value Health*. 2008; 11(5):886–897. [PubMed: 18489513]

52. Sindelar JL, Jofre-Bonet M, French MT, McClellan AT. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. *Drug Alcohol Depend.* 2004; 73:41–50. [PubMed: 14687958]
53. Jofre-Bonet M, Sindelar JL. Creating an aggregate outcome index: cost-effectiveness analysis of substance abuse treatment. *J Behav Health Serv Res.* 2004; 31(3):229–241. [PubMed: 15263863]
54. Kraemer KL, Roberts MS, Horton NJ, et al. Health utility ratings for a spectrum of alcohol-related health states. *Med Care.* 2005; 43:541–550. [PubMed: 15908848]
55. Pinkerton SD, Holtgrave DR, Johnson-Masotti AP, et al. Cost-effectiveness of the NIMH multisite HIV prevention intervention. *AIDS Behav.* 2002; 6:83–96.
56. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. *Health Econ.* 2005; 14(11):1133–1150. [PubMed: 15880389]
57. Mortimer F, Segal L. Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates. *Alcohol Alcohol.* 2005; 40(6):549–555. [PubMed: 16103034]
58. Mortimer D, Segal L. Economic evaluation of interventions for problem drinking and alcohol dependence: do within-family external effects make a difference? *Alcohol Alcohol.* 2006; 41(1): 92–98. [PubMed: 16244100]
59. Storer RM. A simple cost-benefit analysis of brief interventions on substance abuse at Naval Medical Center Portsmouth. *Mil Med.* 2003; 168(9):765–768. [PubMed: 14529255]
60. Anderson P, Scott E. The effect of general practitioner's advice to heavy drinking men. *Br J Addict.* 1992; 87:891–900. [PubMed: 1525531]
61. Senft RA, Polen MR. Brief intervention in a primary care setting for hazardous drinkers. *Am J Prev Med.* 1997; 13(6):464–470. [PubMed: 9415794]
62. Tomson Y, Romelsjo A, Aberg H. Excessive drinking—brief intervention by a primary care nurse. *Scand J Prim Health Care.* 1998; 16:188–192. [PubMed: 9800234]
63. Freeborn DK, Polen MR, Hollis JF, Senft RA. Screening and brief intervention for hazardous drinking in an HMO: effects on medical care utilization. *J Behav Health Serv Res.* 2000; 27:446–453. [PubMed: 11070638]
64. D'Onofrio G, Degutis LC. Preventive care in the emergency department: screening and brief intervention for alcohol problems in the emergency department: a systematic review. *Acad Emerg Med.* 2002; 9(6):627–638. [PubMed: 12045080]
65. Wutzke SE, Congrave KM, Saunders JB, Hall WD. The long-term effectiveness of brief interventions for unsafe alcohol consumption: a 10-year follow-up. *Addiction.* 2002; 97:665–675. [PubMed: 12084136]
66. Copeland LA, Blow FC, Barry KL. Health care utilization by older alcohol-using veterans: effects of a brief intervention to reduce at-risk drinking. *Health Educ Behav.* 2003; 30(3):305–321. [PubMed: 19731498]
67. Crawford MJ, Patton R, Touquet R, et al. Screening and referral for brief intervention of alcohol-misusing patients in an emergency department: a pragmatic randomised controlled trial. *The Lancet.* 2004; 364(9442):1334–1339.
68. Grossberg PM, Brown DD, Fleming MF. Brief physician advice for high-risk drinking among young adults. *Ann Fam Med.* 2004; 2:474–480. [PubMed: 15506584]
69. Shourie S, Conigrave KM, Proude EM, Ward JE, Wutzke SE, Haber PS. The effectiveness of a tailored intervention for excessive alcohol consumption prior to elective surgery. *Alcohol Alcohol.* 2006; 41(6):643–649. [PubMed: 16905552]
70. Lock CA, Kaner E, Heather N, et al. Effectiveness of nurse-led brief alcohol intervention: a cluster randomized controlled trial. *J Adv Nursing.* 2006; 54(4):426–439.
71. Bray JW, Zarkin GA, Davis KL, Mitra D, Higgins-Biddle JC, Babor TF. The effect of screening and brief intervention for risky drinking on health care utilization in managed care organizations. *Med Care.* 2007; 45:177–182. [PubMed: 17224781]
72. Daepfen JB, Gaume J, Bady P, et al. Brief alcohol intervention and alcohol assessment do not influence alcohol use in injured patients treated in the emergency department: a randomized controlled clinical trial. *Addiction.* 2007; 102:1224–1233. [PubMed: 17565563]

73. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2004; 140(7):557–568. [PubMed: 15068985]
74. Mumford E, Schlesinger HJ, Glass GV, Patrick C, Cuerdon T. A new look at evidence about reduced cost of medical utilization following mental health treatment. *Am J Psychiatry.* 1984; 141(10):1145–1158. [PubMed: 6435457]
75. Lennox RD, Scott-Lennox JA, Holder HD. Substance abuse and family illness: evidence from health care utilization and cost-offset research. *J Ment Health Adm.* 1992; 19(1):83–95. [PubMed: 10171039]
76. Olfson M, Sing M, Schlesinger HJ. Mental health/medical care cost offsets: opportunities for managed care. *Health Aff (Millwood).* 1999; 18(2):79–90. [PubMed: 10091434]
77. Holder HD, Blose JO. The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. *J Stud Alcohol.* 1992; 53(4):293–302. [PubMed: 1619923]




Figure 1. Connections between cost, cost-effectiveness, cost-utility, and cost-benefit analysis

Table 1

Key considerations, advantages, and disadvantages of approaches to economic evaluation

Approach	Key Considerations	Advantages	Disadvantages
Cost analysis	Preferable to use systematic data collection tools, such as the Substance Abuse Services Cost Analysis Program (SASCAP)	Allows policy makers to identify cost drivers and draft budgets.	Completing cost tools can be burdensome for researchers and programme staff.
Cost-effectiveness analysis (CEA)	Usefulness depends on which outcome is analyzed. Cost-effectiveness ratios for different treatment outcomes may have different policy implications.	CEAs can yield a ranking of competing alternatives.	The approach does not provide information on the value of a programme independent of alternatives.
Cost-utility analysis (CUA)	Applies to CEA a common metric (e.g., the quality-adjusted life year [QALY]).	QALYs can compare a wide range of diverse programmes.	QALYs are difficult to measure, especially for services expected to have small effects.
Cost-benefit analysis (CBA)	CBAs measure both costs and outcomes in monetary terms, which helps comparisons of screening and brief intervention (SBI) with other types of investments in health and well-being. In practice, CBAs may only put a value on some but not all outcomes.	CBAs can allow direct comparison of costs to benefits. May give clearer guidance than CEAs on which treatment to adopt.	Many outcome measures cannot be expressed in monetary. Benefits of some interventions might be measured more readily than benefits of others, and some benefits may manifest only over several years after treatment.
Analysis of impact on economic outcomes	Typically focuses on the degree to which health care utilization is changed by SBI.	Does not require monetizing either SBI or the outcome.	Unless SBI and outcomes are expressed in money terms, the implications for budget and planning may not be clear.